We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Abbott Diagnostics

  Gold Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Automated Procalcitonin Immunoassay Compared with Four Different Assays

By LabMedica International staff writers
Posted on 05 May 2022
Print article
Image: The Abbott ARCHITECT B•R•A•H•M•S PCT Test for the quantitative determination of PCT (Procalcitonin) in human serum and plasma on the automated ARCHITECT analyzer (Photo courtesy of Fisher Scientific)
Image: The Abbott ARCHITECT B•R•A•H•M•S PCT Test for the quantitative determination of PCT (Procalcitonin) in human serum and plasma on the automated ARCHITECT analyzer (Photo courtesy of Fisher Scientific)

Procalcitonin (PCT) is an important biomarker of sepsis and respiratory infections. An increase in PCT expression in parenchymal tissue can typically be observed in severe bacterial, but not or significantly less, respectively, in viral infections; thus, measurement of plasma PCT concentrations is an important diagnostic tool for clinicians to distinguish between infections from a bacterial versus viral origin.

In addition, plasma PCT measurements are frequently used for antibiotic therapy monitoring which leads to a more efficient use of antibiotic drugs; this, in turn, has beneficial economic effects and reduces the generation of multi-resistant pathogens. Various automated immunoassays for measuring PCT in patient plasma are available in medical laboratories. However, due to a lack of international reference material for PCT, the assays are not always comparable.

Clinical Chemists at the University Medical Center Göttingen (Göttingen, Germany) randomly collected 120 plasma samples from clinical routine laboratory analysis. Parallel PCT measurements of all samples were carried out using five different automated assays on a total of six analyzers: ARCHITECT BRAHMS PCT on the Architect i2000SR (Abbott Diagnostics, Lake Forest, IL, USA), a two-step chemiluminescence microparticle immunoassay (CMIA) using acridinium-labeled conjugates; Abbott Diagnostics’ ALINITY i BRAHMS PCT on the Alinity i, also a CMIA.

DIASYS PCT FS (DiaSys Diagnostic Systems, Holzheim, Germany), a particle-enhanced turbidimetric immunoassay (PETIA) on the Abbott Diagnostics’ Architect c16000 and Alinity c; Elecsys BRAHMS PCT on the Cobas e411 (Roche Diagnostics, Mannheim, Germany), an electro-chemiluminescence immunoassay (ECLIA) in association with a ruthenium complex-conjugated antibody; LIAISON BRAHMS PCT II GEN on the Liaison XL (DiaSorin, Saluggia, Italy), a sandwich chemiluminescence immunoassay using an isoluminol antibody conjugate.

The investigators reported that the DiaSys assay showed clear differences as compared to the BRAHMS-associated assays when measured on Architect c: i.e. 58% positive mean bias versus Architect i, 67% versus Cobas and 23% versus Liaison. As a result, additional 19% the patients would have a suspected bacterial infection, when using PCT values from the DiaSys assay and commonly accepted decision limits. A crosscheck of the DiaSys calibrator on the BRAHMS-associated systems showed a low recovery of the calibrator material (approximately 50%).

The authors concluded overall, their study showed significant differences between the DiaSys and BRAHMS-associated assays. This could be attributed to a potential DiaSys calibrator problem. This highlights the need for an international reference material for harmonization of the PCT assays. The study was published on April 15,2022 in the journal Practical Laboratory Medicine.

Related Links:
University Medical Center Göttingen 
Abbott Diagnostics 
DiaSys Diagnostic Systems 
Roche Diagnostics 

Gold Supplier
Silver Supplier
Urea Breath Test
13C-Urea Breath Test
Silver Supplier
CLIA Microwell Strip Luminometer
LumiStat 4900
Gold Supplier
Automated, Random Access Chemistry Analyzer
LIDA 300

Print article


Molecular Diagnostics

view channel
Image: New chip could make treating metastatic cancer easier and faster (Photo courtesy of Georgia Institute of Technology)

Simple Blood Test Detection Method Could Revolutionize Cancer Treatment

Cancer spreads via circulating tumor cells (CTCs) that travel through the blood to other organs, and they are nearly impossible to track. When a tumor starts metastasizing, it sheds its cell into the blood.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.